At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
Apixabandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Bioavailability of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Apixaban for Healthy Volunteers. Completed, enrolled 48 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the oral bioavailability of Apixaban solution formulation (Treatment B, 10 mg as 25 mL x 0.4 mg/mL) relative to Apixaban tablets (Treatment A, 10 mg as 2 x 5 mg tablets) in healthy subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
Primary CompletionMar 2010
First PostedJan 2014
TodayJul 2026
First PostedJan 13, 2014
Enrollment StartFeb 1, 2010
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 12.5 years ago
Interventions
Apixabandrug